ES2179824T3 - Anticuerpos humanizados reactivos contra el antigeno gpiib/iiia. - Google Patents

Anticuerpos humanizados reactivos contra el antigeno gpiib/iiia.

Info

Publication number
ES2179824T3
ES2179824T3 ES92924918T ES92924918T ES2179824T3 ES 2179824 T3 ES2179824 T3 ES 2179824T3 ES 92924918 T ES92924918 T ES 92924918T ES 92924918 T ES92924918 T ES 92924918T ES 2179824 T3 ES2179824 T3 ES 2179824T3
Authority
ES
Spain
Prior art keywords
gpiib
antibodies against
humanized antibodies
reactive
iiia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92924918T
Other languages
English (en)
Inventor
Man Sung Co
Yun J Tso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
PDL Biopharma Inc
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd, Protein Design Labs Inc filed Critical Yamanouchi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2179824T3 publication Critical patent/ES2179824T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Abstract

Una inmunoglobulina humanizada que tiene las propiedades: [1] existe un epitopo de la mencionada inmunoglobulina humanizada en una glucoproteína GPIIb/IIIa de las plaquetas humanas, [2] no existe un epitopo de la mencionada inmunoglobulina humanizada en las células endoteliales vasculares humanas, [3] dicha inmunoglobulina humanizada tiene una afinidad de unión de 107 M-1 o mayor, y [4] dicha inmunoglobulina humanizada puede bloquear la agregación de las plaquetas humanas en respuesta a los agonistas, donde la mencionada inmunoglobulina humanizada comprende una secuencia que es la región variable madura de la cadena ligera de la secuencia superior en la Figura 5A y una secuencia que es la región variable madura de la cadena pesada de la secuencia superior en la Figura 5B.
ES92924918T 1991-12-20 1992-12-15 Anticuerpos humanizados reactivos contra el antigeno gpiib/iiia. Expired - Lifetime ES2179824T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81211191A 1991-12-20 1991-12-20
US89595292A 1992-06-09 1992-06-09
US94415992A 1992-09-11 1992-09-11

Publications (1)

Publication Number Publication Date
ES2179824T3 true ES2179824T3 (es) 2003-02-01

Family

ID=27420074

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92924918T Expired - Lifetime ES2179824T3 (es) 1991-12-20 1992-12-15 Anticuerpos humanizados reactivos contra el antigeno gpiib/iiia.

Country Status (10)

Country Link
EP (1) EP0619324B1 (es)
JP (1) JP2723671B2 (es)
KR (1) KR100240159B1 (es)
AT (1) ATE220100T1 (es)
AU (1) AU3095892A (es)
CA (1) CA2126182C (es)
DE (1) DE69232669T2 (es)
ES (1) ES2179824T3 (es)
MX (1) MX9207459A (es)
WO (1) WO1993013133A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT676965E (pt) 1992-11-16 2007-10-29 Centocor Inc Método para reduzir a imunogenicidade da região variável de anticorpos
EP0725655B2 (en) * 1993-11-05 2009-04-15 Centocor Inc. Use of compounds capable of binding to glycoprotein gpIIb/IIIa for the prevention of restenosis
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
IL129164A (en) 1996-09-26 2007-05-15 Chugai Pharmaceutical Co Ltd An antibody against peptides associated with human parathyroid hormone
SK155799A3 (en) 1997-05-15 2000-06-12 Chugai Pharmaceutical Co Ltd Cachexia remedy
EP0990034A1 (de) 1997-06-06 2000-04-05 Asat AG Applied Science & Technology Anti-gpiib/iiia rekombinante antikörper
WO2000066160A1 (fr) * 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation
TWI255718B (en) 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration
AU2001252618A1 (en) 2000-04-28 2001-11-12 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors
GB0302699D0 (en) * 2003-02-06 2003-03-12 Univ Bradford Immunoglobulin
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
MX2019004580A (es) 2016-10-21 2019-08-12 Amgen Inc Formulaciones farmaceuticas y metodos para prepararlas.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
NO873164L (no) * 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.

Also Published As

Publication number Publication date
EP0619324A1 (en) 1994-10-12
DE69232669T2 (de) 2003-02-27
CA2126182C (en) 2001-07-17
MX9207459A (es) 1994-03-31
EP0619324B1 (en) 2002-07-03
CA2126182A1 (en) 1993-07-08
KR940703859A (ko) 1994-12-12
EP0619324A4 (en) 1995-11-29
AU3095892A (en) 1993-07-28
ATE220100T1 (de) 2002-07-15
DE69232669D1 (de) 2002-08-08
JP2723671B2 (ja) 1998-03-09
WO1993013133A1 (en) 1993-07-08
KR100240159B1 (ko) 2000-01-15

Similar Documents

Publication Publication Date Title
ATE81153T1 (de) Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern.
BR9507594B1 (pt) anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteìna recombinante.
DK0626447T3 (da) Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen
DE69535243D1 (de) Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
ES2179824T3 (es) Anticuerpos humanizados reactivos contra el antigeno gpiib/iiia.
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
FI903464A0 (fi) Foerfarande foer oxiderande denaturering av proteinanalyter.
DE10299038I1 (de) Plaettchen-Spezifisches Chimaerisches Immunglobulin
DK442888D0 (da) Slaegtspecifikt listeria-antigen identificeret ved hjaelp af monoklone antistoffer
KR890016165A (ko) 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도
DE3850993T2 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
DK329789D0 (da) Monoklonalt antistof
DK0513565T3 (da) Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse
ATE110786T1 (de) Monoklonaler antikörper gegen exotoxin a von pseudomonas aeruginosa.
EP0332421A3 (en) Monoclonal antibodies recognizing human psti, hybridomas producing the same, and their preparation and use